Altered transcription of the stem cell leukemia gene in myelofibrosis with myeloid metaplasia

Leukemia

Volumn 17, Issue 10, 2003, Pages 1998-2006

  Steunou, V ^a   Le Bousse Kerdiles M C ^b   Colin Micouin, A ^a   Clay, D ^b   Chevillard, S ^c   Martyre M C ^a  

^a INSTITUT CURIE   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Myelofibrosis; Myeloproliferation; SCL

Indexed keywords

ISOPROTEIN; TRANSCRIPTION FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CD34 ANTIGEN; DNA; DNA BINDING PROTEIN; LEUKOCYTE ANTIGEN; ONCOPROTEIN; PRIMER DNA; TAL1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL COUNT; CELL ISOLATION; CELL LINEAGE; CELL POPULATION; CELL SELECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENETICS; HEMATOPOIETIC STEM CELL; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, CD34; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA PRIMERS; DNA, NEOPLASM; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; MYELOFIBROSIS; MYELOID METAPLASIA; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0142213387     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403089     Document Type: Article

References (51)

1. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guide lines. J Clin Oncol 1999; 17: 2954-2970.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265.
3. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of haematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194.
4. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haemat 1999; 80: 184-188.
5. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. In: Berck P, Castro-Malaspina H, Wasserman LR (eds). Myelofibrosis and the Biology of Connective Tissue. New York: Alan R. Liss, 1984 pp 427-454.
6. Martyré MC, Romquin N, Le Bousse-Kerdilès MC, Chevillard S, Benyahia B, Dupriez B et al. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88: 9-16.
7. Martyré MC, Le Bousse-Kerdilès C, Romquin N, Chevillard S, Praloran V, Demory JL et al. Elevated levels of basic growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997; 97: 441-448.
8. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984; 57: 495-503.
9. Han ZC, Brière J, Nedellec G, Abgrall JF, Sensèbe L, Parent D et al. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur J Haematol 1988; 40: 130-135.
10. Le Bousse-Kerdilès MC, Martyré MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. Semin Immunopathol 2000; 21: 491-508.
11. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98: 96-102.
12. Kehrl JH. Haematopoietic lineage commitment: role of transcription factors. Stem Cells 1995; 13: 223-241.
13. Begley CG, Green AR. The SCL gene: from case report to critical haematopoietic regulator. Blood 1999; 93: 2760-2770.
14. Elwood NJ, Cook WD, Metcalf D, Begley CG. SCL, the gene implicated in T-cell leukemia is oncogenic in a murine T-lymphocyte cell line. Oncogene 1993; 8: 3093-3101.
15. Condorelli GL, Facchiano F, Valtieri M, Proietti E, Vitelli L, Lulli V et al. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res 1996; 56: 5113-5119.
16. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin S. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all haematopoietic lineages. Cell 1996; 86: 47-57.
17. Cross MA, Heyworth CM, Murrell AM, Bockamp E-O, Dexter TM, Green AR. Expression of lineage restricted transcription factors precedes lineage specific differentiation in a multipotent haematopoietic progenitor cell line. Oncogene 1994; 9: 3013-3016.
18. Cheng T, Shen H, Giokas D, Gere J, Tenen DG, Scadden DT. Temporal mapping of gene expression levels during the differentiation of individual primary haematopoietic cells. Proc Natl Acad Sci USA 1996; 93: 13158-13163.
19. Aplan PD, Nakarah K, Orkin SH, Kirsch I. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J 1992; 11: 4073-4081.
20. Bockamp E-O, McLaughlin F, Göttgens B, Robb L, Begley CG, Green AR. Lineage-restricted regulation of the murine SCL/TAL-1 promoter. Blood 1995; 86: 1502-1514.
21. Mouthon MA, Bernard O, Mitjavila MT, Romeo PH, Vainchenker W, Mathieu-Mahul D. Expression of tal-1 and GATA-binding proteins during human haematopoiesis. Blood 1993; 81: 647-655.
22. Bockamp E-O, McLaughlin F, Göttgens B, Murrell A, Elefanty AG, Green AR. Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. J Biol Chem 1997; 272: 8781-8790.
23. Bernard O, Azogui O, Lecointe N, Mugneret F, Berger R, Larsen CJ et al. A third tal-1 promoter is specifically used in human T cell leukemias. J Exp Med 1992; 176: 919-925.
24. Courtes C, Lecointe N, Le Cam L, Baudoin F, Sardet C, Mathieu-Mahul D. Erythroid-specific inhibition of the tal-1 intragenic promoter is due to binding of a repressor to a novel silencer. J Biol Chem 2000; 275: 949-958.
25. Cheng JT, Hsu HL, Hwang LY, Baer R. Products of the TAL1 oncogene: basic helix-loop-helix proteins phosphorylated at serine residues. Oncogene 1993; 8: 677-683.
26. Martyré MC. TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leukemia Lymphoma 1995; 20: 39-44.
27. Hsu HL, Huang L, Tsan JT, Funk W, Wright WE, Hu JS et al. Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins. Mol Cell Biol 1994; 14: 1256-1265.
28. Pulford K, Lecointe N, Leroy-Viard K, Mathieu-Mahul D, Mason DY. Expression of TAL-1 proteins in human tissues. Blood 1995; 85: 675-684.
29. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990; 11: 231-238.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Ann Biochem 1987; 162: 156-159.
31. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996; 88: 4534-4546.
32. Vav associates with the type I interferon receptor and contributes to the antiproliferative effect of IFN-α in megakaryocytic cell lines. Oncogene 2000; 19: 387-394.
33. Tropel P, Roullot V, Vernet M, Poujol C, Pointu H, Nurden P et al. 27-kb portion of the 5′ flanking region of the murine glycoprotein αIIb gene is transcriptionally active in primitive haematopoietic progenitor cells. Blood 1997; 8: 2995-3004.
34. Fraser JK, Leahy MF, Berridge MV. Expression of antigens of the platelet glycoprotein IIb/IIIa complex on human haematopoietic stem cells. Blood 1986; 68: 762-769.
35. Ody C, Vaigot P, Quéré P, Imhof BA, Corbel C. Glycoprotein IIb-IIIa is expressed on avian multilineage haematopoietic progenitor cells. Blood 1999; 93: 2888-2906.
36. Debili N, Robin C, Schiavon V, Letestu R, Pflumio F, Mitjavila-Garcia MT et al. Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. Blood 2001; 97: 2023-2030.
37. Murray LJ, Mandich D, Bruno E, DiGiusto RK, Fu WC, Sutherland DR et al. Fetal bone marrow CD34+CD41+ cells are enriched for multipotent haematopoietic progenitors, but not for pluripotent stem cells. Exp Hematol 1996; 24: 236-245.
38. Göttgens B, McLaughlin F, Bockamp E-O, Fordham JL, Begley CG, Kosmopoulos K et al. Transcription of the SCL gene in erythroid and CD34 positive primitive myeloid cells is controlled by a complex network of lineage-restricted chromatin-dependent and chromatin-independent regulatory elements. Oncogene 1997; 15: 2419-2428.
39. Aplan PD, Begley CG, Bertness V, Nussmeier M, Ezquerra A, Coligan J et al. The SCL gene is formed from a transcriptionally complex locus. Mol Cell Biol 1990; 10: 6426-6435.
40. Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000; 183: 145-154.
41. Pulford K, Lecointe N, Leroy-Viard K, Jones M, Mathieu-Mahul D, Mason D. Expression of TAL-1 proteins in human tissues. Blood 1995; 85: 675-684.
42. Goldfarb AN, Goueli S, Mickelson D, Greenberg JM. T-cell acute lymphoblastic leukemia-the associated gene SCL/tal-1 codes for a 42 kD nuclear phosphoprotein. Blood 1992; 80: 2858-2866.
43. Karin M. Signal transduction from cell surface to nucleus in development and disease. FASEB J 1992; 6: 2581-2590.
44. Valtieri M, Tocci A, Gabbianelli M, Luchetti L, Masella B, Vitelli L et al. Enforced TAL-1 expression stimulates primitive, erythroid, and megakaryocytic progenitors but blocks the granulopoietic differentiation program. Cancer Res 1998; 58: 562-569.
45. Elwood NJ, Zogos H, Pereira DS, Dick J, Begley CG. Enhanced megakaryocyte and erythroid development from normal human CD34+ cells: consequence of enforced expression of SCL. Blood 1998; 10: 3756-3765.
46. Krosl G, He G, Lefrancois M, Charron F, Roméo PH, Jolicoeur P et al. Transcription factor SCL is required for c-kit expression and c-kit function in hemopoietic cells. J Exp Med 1998; 188: 439-450.
47. Sittonen T, Savolainen ER, Koistinen P. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplasic syndromes. Leukemia 1994; 8: 631-637.
48. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995; 91: 661-663.
49. Mikkola HK, Fujiwara Y, Schlaeger TM, Travis D, Orkin SH. Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse embryo. Blood 2003; 101: 508-516.
50. low mice). Blood 2002; 100: 1123-1132.
51. + hematopoietic progenitors from patients with idiopathic myelofibrosis. Blood 2003;